Loading clinical trials...
Loading clinical trials...
A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertuzumab in Combination With Standard (Neo)Adjuvant Treatment in Patients With Operable HER2+/HR+ Breast Cancer.
Conditions
Interventions
Perjeta Injectable Product
Herceptin
+18 more
Locations
1
Germany
Evangelisches Krankenhaus Bethesda Mönchengladbach
Mönchengladbach, Germany
Start Date
October 5, 2017
Primary Completion Date
July 14, 2020
Completion Date
March 4, 2024
Last Updated
April 17, 2024
NCT07191730
NCT06312176
NCT06797635
NCT07003841
NCT07396766
NCT06443645
Lead Sponsor
Palleos Healthcare GmbH
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions